Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

APK Mutant: A Single Arm Phase II Study of Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

NCT04853043 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT04853043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04853043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
APK Mutant: A Single Arm Phase II Study of Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Terminated
Start date
November 3, 2021
Completion date
May 3, 2024
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer